Patents by Inventor Celia A. Whitesitt

Celia A. Whitesitt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting alpha- amyloid peptide release and/or its synthesis by use of such compounds
    Patent number: 6399628
    Abstract: Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
    Type: Grant
    Filed: March 12, 1999
    Date of Patent: June 4, 2002
    Assignees: Athena Neurosciences, Inc., Eli Lilly & Company
    Inventors: James E. Audia, Beverly K. Folmer, Varghese John, Lee H. Latimer, Jeffrey S. Nissen, Jon K. Reel, Eugene D. Thorsett, Celia A. Whitesitt
  • Treatment of alzheimer's disease employing inhibitors of cathepsin D
    Patent number: 6251928
    Abstract: This invention provides novel benzylidene rhodanines which are useful as agents in treating or preventing conditions associated with &bgr;-amyloid peptide. This invention further provides methods of treating or preventing Alzheimer's Disease which comprises administering to a mammal in need thereof an effective amount of one or more of the benzylidene rhodanines of the present invention.
    Type: Grant
    Filed: March 16, 1994
    Date of Patent: June 26, 2001
    Assignee: Eli Lilly and Company
    Inventors: Jill A. Panetta, Michael L. Phillips, Jon K. Reel, John K. Shadle, Sandra K. Sigmund, Richard L. Simon, Celia A. Whitesitt
  • Heterocyclic compounds and their use
    Patent number: 6194416
    Abstract: The present invention relates to therapeutically active compounds of the formula: wherein G is an azacyclic or azabicyclic ring system, W is oxygen or sulfur, r is 0, 1, or 2, and R is defined in the specification; and to methods of treatment using, and pharmaceutical compositions comprising, these compounds. The novel compounds are useful in treating diseases in the central nervous system caused by malfunctioning of the muscarinic cholinergic system.
    Type: Grant
    Filed: April 10, 1997
    Date of Patent: February 27, 2001
    Assignee: Eli Lilly and Company
    Inventors: Leander Merritt, Jon K. Reel, John S. Ward, Celia A. Whitesitt
  • Heterocyclic compounds
    Patent number: 6124312
    Abstract: The present invention provides heterocyclic 2-aza-bicyclo[2.2.1]heptane compounds which are useful for modulating a muscarinic ptor.
    Type: Grant
    Filed: June 1, 1999
    Date of Patent: September 26, 2000
    Assignee: Eli Lilly and Company
    Inventors: Charles H Mitch, Steven J Quimby, Jon K Reel, Celia A Whitesitt
  • Heterocyclic compounds
    Patent number: 6117883
    Abstract: The present invention provides heterocyclic compounds which are useful for modulating a muscarinic receptor.
    Type: Grant
    Filed: August 30, 1999
    Date of Patent: September 12, 2000
    Assignee: Eli Lilly and Company
    Inventors: Leander Merritt, Jon K Reel, Celia A Whitesitt, Richard L Simon
  • N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting .beta.-amyloid peptide release and/or its synthesis by use of such compounds
    Patent number: 5965614
    Abstract: Disclosed are compounds which inhibit .beta.-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits .beta.-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
    Type: Grant
    Filed: November 21, 1997
    Date of Patent: October 12, 1999
    Assignee: Athena Neurosciences, Inc.
    Inventors: James E. Audia, Beverly K. Folmer, Varghese John, Lee H. Latimer, Jeffrey S. Nissen, Jon K. Reel, Eugene D. Thorsett, Celia A. Whitesitt
  • Inhibitors of amyloid beta-protein production
    Patent number: 5814646
    Abstract: A method of protecting a warm-blooded mammal from the progression of Alzheimer's disease, which comprises administering an effective amount of a compound of general formula. ##STR1## in which: R.sup.1 represents an optionally substituted aromatic or heteroaromatic group;L.sup.1 and L.sup.2 each independently represents a bond or an unbranched (1-4C) alkylene group, which alkylene group may optionally bear a (1-4C) alkyl, phenyl or phenyl (1-2C) alkyl substituent;one of Y.sup.1 and Y.sup.2 represents NR.sup.3 and the other represents O, S or NR.sup.3, in which R.sup.3 represent hydrogen, hydroxyl, (1-4C) alkoxy, (1-4C) alkyl or di (1-4C) alkylamino;Z represents O or S; andR.sup.2 represents (3-8C) cycloalkyl, heterocyclyl, and optionally substituted aromatic or heteroaromatic group, or together with L.sup.2, (1-10C) alkyl;or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 2, 1995
    Date of Patent: September 29, 1998
    Assignee: Eli Lilly and Company
    Inventors: Lawrence J. Heinz, Jill A. Panetta, Michael L. Phillips, Jon K. Reel, John K. Shadle, Richard L. Simon, Celia A. Whitesitt
  • Benzylidene rhodanines
    Patent number: 5747517
    Abstract: This invention provides novel benzylidene rhodanines which are useful as agents in treating or preventing conditions associated with .beta.-amyloid peptide. This invention further provides methods of treating or preventing Alzheimer's Disease which comprises administering to a mammal in need thereof an effective amount of one or more of the benzylidene rhodanines of the present invention.
    Type: Grant
    Filed: September 11, 1996
    Date of Patent: May 5, 1998
    Assignee: Eli Lilly and Company
    Inventors: Jill A. Panetta, Michael L. Phillips, Jon K. Reel, John K. Shadle, Sandra K. Sigmund, Richard L. Simon, Celia A. Whitesitt
  • Angiotensin II antagonists
    Patent number: 5693633
    Abstract: This invention provides novel heterocyclic derivatives, their pharmaceutical formulations, and their use for antagonizing angiotensin II receptors in mammals.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: December 2, 1997
    Assignee: Eli Lilly and Company
    Inventors: Donald B. Boyd, Sherryl L. Lifer, Winston S. Marshall, Alan D. Palkowitz, William Pfeifer, Jon K. Reel, Richard L. Simon, Mitchell I. Steinberg, K. Jeff Thrasher, Venkatraghavan Vasudevan, Celia A. Whitesitt
  • Chemical compounds as inhibitors of amyloid beta protein production
    Patent number: 5624937
    Abstract: A compound of the formula I in which ##STR1## Z is O or S; R.sup.11 is a halogen atom;R.sup.12 is a halogen atom or a trifluoromethyl group; andX is S, SO, SO.sub.2, O or NH;R.sup.4 is naphthyl, quinolinyl, benzimidazolyl, pyridyl, pyradazinyl, benzoxazolyl or benzothiazolyl, unsubstituted or substituted by one or two substituents selected from a halogen atom, (1-4C)alkyl, (1-4C)alkoxy, nitro, (1-4C)alkoxycarbonyl, halo(1-4C)alkyl, and phenyl;or a pharmaceutically acceptable salt thereof.The compounds are useful as inhibitors of amyloid beta-protein production.
    Type: Grant
    Filed: March 2, 1995
    Date of Patent: April 29, 1997
    Assignee: Eli Lilly and Company
    Inventors: Jon K. Reel, Richard L. Simon, Celia A. Whitesitt
  • Angiotensin II antagonists
    Patent number: 5612360
    Abstract: This invention provides novel heterocyclic derivatives, their pharmaceutical formulations, and their use for antagonizing angiotensin II receptors in mammals.
    Type: Grant
    Filed: April 20, 1993
    Date of Patent: March 18, 1997
    Assignee: Eli Lilly and Company
    Inventors: Donald B. Boyd, Sherryl L. Lifer, Winston S. Marshall, Alan D. Palkowitz, William Pfeifer, Jon K. Reel, Richard L. Simon, Mitchell I. Steinberg, K. Jeff Thrasher, Venkatraghavan Vasudevan, Celia A. Whitesitt
  • Angiotensin II antagonists
    Patent number: 5571925
    Abstract: This invention provides novel phenyl and heterocyclic derivatives, their pharmaceutical formulations and their use for antagonizing angiotensin II receptors in mammals.
    Type: Grant
    Filed: January 19, 1994
    Date of Patent: November 5, 1996
    Assignee: Eli Lilly and Company
    Inventors: Sherryl L. Lifer, Winston S. Marshall, Fariborz Mohamadi, Jon K. Reel, Richard L. Simon, Mitchell I. Steinberg, Celia A. Whitesitt
  • Angiotensin II antagonists
    Patent number: 5569768
    Abstract: This invention provides novel heterocyclic derivatives, their pharmaceutical formulations, and their use for antagonizing angiotensin II receptors in mammals.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: October 29, 1996
    Assignee: Eli Lilly and Company
    Inventors: Donald B. Boyd, Sherryl L. Lifer, Winston S. Marshall, Alan D. Palkowitz, William Pfeifer, Jon K. Reel, Richard L. Simon, Mitchell I. Steinberg, K. Jeff Thrasher, Venkatraghavan Vasudevan, Celia A. Whitesitt
  • Angiotensin II antagonists
    Patent number: 5563278
    Abstract: This invention provides novel phenyl and heterocyclic derivatives, their pharmaceutical formulations and their use for antagonizing angiotensin II receptors in mammals.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: October 8, 1996
    Assignee: Eli Lilly and Company
    Inventors: Sherryl L. Lifer, Winston S. Marshall, Fariborz Mohamadi, Jon K. Reel, Richard L. Simon, Mitchell I. Steinberg, Celia A. Whitesitt
  • Angiotensin II antagonist intermediates
    Patent number: 5556981
    Abstract: This invention provides novel heterocyclic derivatives, their pharmaceutical formulations, and their use for antagonizing angiotensin II receptors in mammals.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: September 17, 1996
    Assignee: Eli Lilly and Company
    Inventors: Donald B. Boyd, Sherryl L. Lifer, Winston S. Marshall, Alan D. Palkowitz, William Pfeifer, Jon K. Reel, Richard L. Simon, Mitchell I. Steinberg, K. Jeff Thrasher, Venkatraghaven Vasudevan, Celia A. Whitesitt
  • Angiotensin II antagonists
    Patent number: 5484780
    Abstract: This invention provides novel phenyl and heterocyclic derivatives, their pharmaceutical formulations and their methods of use for antagonizing angiotensin II receptors in mammals.
    Type: Grant
    Filed: December 14, 1994
    Date of Patent: January 16, 1996
    Assignee: Eli Lilly and Company
    Inventors: Donald B. Boyd, Kenneth L. Hauser, Sherryl L. Lifer, Winston S. Marshall, Alan D. Palkowitz, William Pfeifer, Jon K. Reel, Richard L. Simon, Mitchell I. Steinberg, Kumiko Takeuchi, K. Jeff Thrasher, Celia A. Whitesitt
  • Angiotensin II antagonists
    Patent number: 5401851
    Abstract: This invention provides novel phenyl and heterocyclic derivatives, their pharmaceutical formulations and their methods of use for antagonizing angiotensin II receptors in mammals.
    Type: Grant
    Filed: April 20, 1993
    Date of Patent: March 28, 1995
    Assignee: Eli Lilly and Company
    Inventors: Donald B. Boyd, Kenneth L. Hauser, Sherryl L. Lifer, Winston S. Marshall, Alan D. Palkowitz, William Pfeifer, Jon K. Reel, Richard L. Simon, Mitchell I. Steinberg, Kumiko Takeuchi, K. Jeff Thrasher, Celia A. Whitesitt
  • Angiotensin II antagonists
    Patent number: 5312936
    Abstract: This invention provides novel phenyl and heterocyclic derivatives, their pharmaceutical formulations and their use for antagonizing angiotensin II receptors in mammals.
    Type: Grant
    Filed: September 17, 1991
    Date of Patent: May 17, 1994
    Assignee: Eli Lilly and Company
    Inventors: Sherryl L. Lifer, Winston S. Marshall, Fariborz Mohamadi, Jon K. Reel, Richard L. Simon, Mitchell I. Steinberg, Celia A. Whitesitt
  • Angiotensin II antagonist 1,3-imidazoles and use thereas
    Patent number: 5073566
    Abstract: This invention provides novel phenyl and heterocyclic derivatives, their pharmaceutical formulations and their use for antagonizing angiotensin II receptors in mammals.
    Type: Grant
    Filed: November 30, 1989
    Date of Patent: December 17, 1991
    Assignee: Eli Lilly and Company
    Inventors: Sherryl L. Lifer, Winston S. Marshall, Fariborz Mohamadi, Jon K. Reel, Richard L. Simon, Mitchell I. Steinberg, Celia A. Whitesitt
  • Disubstituted tetrazole leukotriene antagonists and methods for their use thereas
    Patent number: 4820723
    Abstract: The instant invention provides disubstituted tetrazoles that antagonizes the effect of leukotrienes C.sub.4, D.sub.4 or E.sub.4 or any combination thereof in selected tissues. The disubstituted tetrazoles are used in pharmaceutical formulations and methods of treatment of conditions caused by excessive release or production of leukotrienes C.sub.4, D.sub.4 or E.sub.4 or any combination thereof. Such conditions include an immediate hypersensitivity reaction of the type represented by asthma, or by shock or other adverse cardiovascular effects.
    Type: Grant
    Filed: August 14, 1987
    Date of Patent: April 11, 1989
    Assignee: Eli Lilly and Company
    Inventors: Winston S. Marshall, Sandra K. Sigmund, Celia A. Whitesitt